Short answer
Scholar Rock Holding Corp (SRRK) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $570,000 with net income of −$107M.
Q3 2026 key financials · XBRL
- Revenue
- $570,000
- Net income
- −$107M
- −4.9% YoY · +2.4% QoQ
- Operating margin
- -18607.2%
- EPS (diluted)
- −$0.81
- +9.0% YoY · +3.6% QoQ
Source: XBRL data from the Scholar Rock Holding Corp (SRRK) Q3 2026 10-Q on SEC EDGAR. USD.
Scholar Rock Holding Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $0.6M from ISEMBYLD, versus $0 in Q3 2025
- Gross margin approximately 98.7%, based on $0.6M revenue and $8,000 cost of revenue
- Best-performing program SRK-439 R&D costs $2.9M, up 77.4% YoY; apitegromab costs $20.0M, down 6.5%
- Cash, equivalents and marketable securities $413.6M, up $46.0M from December 31, 2025
- Operating cash use $234.2M; financing provided $280.0M, including $160.8M ATM proceeds and $197.7M debt proceeds
Risk Factors
- Newly added commercialization risk: FDA approved ISEMBYLD on September 11, 2026, making U.S. launch execution critical to revenue and profitability
- Most material regulatory update: third-party fill-finish facility received OAI classifications in 2025 and 2026, delaying EU approval and forcing MAA resubmission
- Regulatory pricing risk: CMS finalized GLOBE on October 2, 2026, requiring incremental Medicare Part B rebates beginning January 1, 2027
- Near-term operational risk: single-source apitegromab drug substance and fill-finish suppliers expose commercial supply to disruptions and batch failures
- Financial risk: ongoing net losses and additional capital requirements remain necessary to fund ISEMBYLD commercialization and pipeline development
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Scholar Rock Holding Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.